What Jim Kelly's Story Can Teach Us About Oral and Head and Neck Cancer

What Jim Kelly and his family made public

The Buffalo Bills quarterback Jim Kelly was first diagnosed with squamous cell carcinoma in June 2013. NBC News, carrying an Associated Press report, laid out the sequence. The first operation removed part of his upper jaw.

Follow-up tests nine months later showed the cancer had spread to his sinus. That led to radiation and chemotherapy. He lost 70 pounds. The effects of the cancer and the treatment left him with trouble speaking, no saliva, and no sense of taste.

He was cancer-free from September 2014, with routine follow-up testing required. On March 1, 2018, that testing found cancer again. Kelly said he was "shocked and deeply saddened," and asked for prayers: "With all of you by my side, we will fight and win this battle together." His wife, Jill, wrote on Instagram: "We are shocked, heartbroken, sad, angry, confused and just darn tired."

That is what they chose to share, and this article does not go beyond it. The medicine here is unusually instructive, because it covers the part of cancer care nobody advertises: what happens for years afterward.

Where "oral cancer" actually sits

The oral cavity is not one place. The National Cancer Institute's clinician guidance divides it into the lip, the front two-thirds of the tongue, the inner cheek lining, the floor of the mouth, the upper and lower gums, the retromolar trigone behind the last molars, and the hard palate.

Most cancers here are squamous cell carcinomas, which start in the flat cells lining those surfaces. Kelly's disease involved the upper jaw, the maxilla, which sits directly beneath the sinuses. That anatomy matters. Structures in the head sit close together, so a tumor that grows a short distance can cross into a different compartment.

When to get checked

NCI notes something important: lip and oral cavity cancer may have no symptoms at all, and is sometimes found during a regular dental exam. When there are signs, NCI says to check with a doctor about any of these:

• A sore on the lip or in the mouth that does not heal.
• A lump or thickening on the lips, on the gums, or in the mouth.
• A white or red patch on the gums, tongue, or lining of the mouth.
• Bleeding, pain, or numbness in the lip or mouth.
• A change in voice.
• Loose teeth, or dentures that no longer fit well.
• Trouble chewing, swallowing, or moving the tongue or jaw.
• Swelling of the jaw.
• A sore throat, or a feeling that something is caught in the throat.

Attach a number to that list. The NHS uses three weeks: a mouth ulcer lasting longer than that should be seen. Three weeks is short enough to be early, and long enough for ordinary injuries to heal.

Two of those signs get rationalized away. Dentures that suddenly stop fitting are not just old dentures. Numbness in a lip is not nothing.

How a diagnosis is made

NCI describes an examination that is mostly hands and light. A doctor or dentist feels the whole inside of the mouth with a gloved finger and inspects it with a small mirror. That covers the cheeks, lips, gums, roof and floor of the mouth, and all sides of the tongue. The neck is felt for swollen lymph nodes.

From there, NCI lists endoscopy, biopsy, exfoliative cytology, which scrapes cells for examination, and imaging with MRI, CT, PET, or a barium swallow.

Two pathology findings shape what follows. NCI's clinician guidance says a positive surgical margin, or a tumor depth of invasion greater than 5 mm, significantly raises the risk of local recurrence. Extranodal extension, meaning cancer that has broken through the outer wall of a lymph node, is a significant adverse prognostic factor and is built into current staging.

Why follow-up does not end

Kelly's later diagnoses were found by scheduled testing, not by symptoms. That is the argument for surveillance.

NCI's guidance on oral complications makes the after-treatment task explicit. For people who have had high-dose head and neck radiation, clinicians are advised to monitor for the risk of osteoradionecrosis, meaning bone that dies from radiation damage, and for recurrent or new oral mucosal malignancy.

That last phrase carries weight. A second cancer in the mouth is not always the first one coming back. The same surfaces, exposed to the same risk factors, can grow a new and separate tumor. Both possibilities are why surveillance runs for years.

What treatment leaves behind

For stage I and II lip and oral cavity cancer, NCI reports that surgery and radiation give similar cure rates, in the range of 70% to 100%. Stage III and IV disease usually needs both. When a tumor cannot be removed, NCI reports that concurrent chemotherapy and radiation gave an 8% absolute survival advantage over radiation alone.

The lasting effects rarely make the news. Radiation here can permanently reduce saliva, change or erase taste, stiffen the jaw, and damage teeth and bone. Kelly described losing saliva and taste, and having trouble speaking.

NCI's protocol for this is practical. Before high-dose head and neck radiation, advanced dental decay is treated, moderate or severe gum disease is managed, and dentures or appliances that could injure the mouth lining are corrected. During treatment, mucositis, the painful inflammation of the mouth lining, is managed actively, and patients are prescribed jaw opening and closing exercises to reduce the risk of trismus, a permanent tightening of the jaw.

NCI describes the team for this work as interprofessional: oncologists, oncology nurses, dentists, dental hygienists, social workers, and dietitians. NCI also notes that smoking during radiation therapy reduces how well the radiation works.

What the population numbers look like

These describe groups, not individuals. For 2026 the American Cancer Society projects 60,480 new oral cavity and pharynx cancers in the United States, about 2.9% of all new cancers, and 13,150 deaths; SEER, NCI's cancer surveillance program, lists them. Five-year relative survival across all stages is 69.9% for people diagnosed from 2016 to 2022, and the median age at diagnosis is 65.

Stage tells the rest. SEER records five-year relative survival of 88.7% when the cancer is still localized, 69.7% at the regional stage, and 36.0% once it is distant. Only about 26% are found localized. More than half are already regional.

That distribution, not any one person's course, is what the three-week rule aims to change.

Sources

• NCI: Lip and Oral Cavity Cancer Treatment (PDQ) — Health Professional Version
• NCI: Lip and Oral Cavity Cancer Treatment (PDQ) — Patient Version
• NCI: Oral Complications of Cancer Therapies (PDQ) — Health Professional Version
• SEER Cancer Stat Facts: Oral Cavity and Pharynx Cancer
• NHS: Symptoms of mouth cancer
• NBC News: NFL Hall of Famer Jim Kelly says tests show return of oral cancer